The medicine is intended to help manage symptoms associated with fungal infections, particularly those caused by Candida species. The primary therapeutic domains include skin and mucosal candidiasis, vulvovaginitis, balanoposthitis, and candidiasis of the intestines. These conditions are typically caused by an overgrowth of susceptible yeast and mold.

The clinical uses focus on managing local fungal overgrowth that leads to patient discomfort. The medication works to address the proliferation of the causative organism. The intended benefit is to help relieve common symptoms, such as itching, burning, and discharge, with the goal of improving comfort and quality of life. This information is based on approved medical uses.

Quick Fact: Relief for Mucosal Irritation

“The medication helps control the symptoms associated with an overgrowth of susceptible yeast.”

Official Population Eligibility for Пимафуцин (Natamycin)

Category	Official Regulatory Statement
Populations for whom use is allowed	Use is established in adults for various locally acting formulations. No restrictions are generally listed for older adults (geriatric population).
Populations for whom use is contraindicated	Individuals with a history of hypersensitivity (allergy) to Natamycin (Pimaricin) or any of the inactive components (excipients).
Age-related eligibility rules	Use is established in adults. Safety and effectiveness in pediatric patients have not been established for some formulations, reflecting a lack of data.
Pregnancy and lactation eligibility status	In pregnancy, use should be considered only if clearly needed. Caution is officially advised during lactation because it is not known whether Natamycin is excreted in human milk.
Organ function restrictions	No specific limitations are mandated in official labeling for patients with hepatic impairment or renal impairment, a status related to the drug's minimal systemic absorption.

The official eligibility profile is strictly defined by adherence to the absolute contraindication against hypersensitivity. Regulatory documents categorize use as established in adults and generally not restricted in older adults or in cases of organ impairment. Eligibility for use in pediatric, pregnant, or nursing populations is constrained by the official status of safety data, requiring caution or use only when clearly necessary, as documented by national health authorities.

Interactions with other medicines and products

The official regulatory interaction profile for Natamycin (Пимафуцин) is characterized by its documented negligible systemic absorption across all routes of administration, including topical, vaginal, oral for intestinal use, and ophthalmic. This pharmacokinetic property is the formal basis for the absence of systemic interaction warnings in official labeling.

Interaction Scope and Restrictions

Category	Official Constraint / Regulatory Statement
Pharmacokinetic/Metabolic	None documented. Systemic metabolic interactions involving CYP enzymes or drug transporters are not expected due to minimal systemic exposure.
Pharmacodynamic	Topical or Ophthalmic Corticosteroids are subject to formal restriction or contraindication in some labels. This is a documented pharmacodynamic restriction due to the risk of worsening the fungal infection.
Timing-Based Rules	Co-administration with other local ophthalmic preparations requires a procedural constraint for separation: a time interval of at least 5 to 10 minutes is necessary to prevent the washout of the Natamycin dose.
Food, Alcohol, Supplements	None documented in official prescribing information.
Population-Specific Notes	None documented. Constraints related to patient populations (e.g., hepatic or renal impairment) are not applicable due to the lack of systemic effect.

Connection to the Overall Interaction Profile

The lack of systemic drug–drug interaction warnings is structurally consistent with the documented minimal systemic bioavailability of Natamycin. The few constraints that are documented relate exclusively to the local site of action, defining mandatory timing rules for co-administered local treatments and restricting the use of antagonistic drug classes like local corticosteroids.

How Пимафуцин Works

The fungicidal action of Натамицин (Natamycin) is based on an irreversible perturbation of the fungal cell membrane, initiating a cascade of molecular failures resulting in fungal cell death.

Selective Targeting of Fungal Ergosterol

Natamycin is a polyene macrolide that exerts its mechanism by binding with high affinity to ergosterol, a sterol molecule unique to the membranes of sensitive yeasts and molds. The highly selective interaction is based on the presence of ergosterol in the fungal membrane, which is absent in human cells that contain cholesterol.

Disruption of Membrane Dynamics and Integrity

The binding of Natamycin promotes its clustering within the fungal membrane, severely perturbing the local lipid packing and structural integrity in a non-pore-forming manner. This disruption inhibits crucial membrane-dependent processes, notably vacuole fusion and the function of nutrient transporters. This leads to the loss of cellular homeostasis.

Localized Fungicidal Activity

The cumulative effect of these molecular and cellular failures—the loss of barrier function and metabolic capacity—results in fungicidal activity. This action is constrained to the site of application because Natamycin exhibits negligible systemic absorption, confining the fungicidal activity to the site of application.

How Пимафуцин is Used: Official Administration Guidelines

Administration of Natamycin-based products, such as Пимафуцин, is strictly localized, with the dosage form dictating the official route of application. The information below details the standardized usage instructions.

Official Routes and Dosage Forms

Dosage Form	Approved Route	Standard Dose / Strength
Vaginal Suppository	Vaginal	1 suppository (100 mg Natamycin)
Cream	Topical (Dermal/Mucosal)	Thin layer (20 mg/g concentration)
Oral Tablet	Oral	1 tablet (100 mg Natamycin)
**Ophthalmic Suspension***	Topical Ophthalmic	5% Suspension (50 mg/mL)

• Note: Ophthalmic formulation is a separate product containing Natamycin.

---

Standard Dosing Frequency and Duration

Official dosing is designed for localized action, and regimens vary by the application site:

• Vaginal Candidiasis: The standard regimen is 1 vaginal suppository once daily, typically administered deep into the vagina at bedtime. Treatment duration is generally prescribed for 3 to 6 days.
• Skin/Mucosal Infections (Cream): Apply a thin layer to the affected area 1 to 4 times per day. The typical duration of use is 2 to 3 weeks, continuing for a few days after all physical signs have resolved.
• Ophthalmic Use: For severe keratitis, the initial dose is one drop of the 5% suspension hourly or two-hourly, with frequency reduced to 6 to 8 times daily after 3 to 4 days. The therapy course usually lasts 14 to 21 days.

Administration Conditions

1. Preparation: The ophthalmic suspension must be shaken well before using.
2. Special Condition: The oral tablets, intended for intestinal action, may be taken with or without food. Due to minimal systemic absorption, no routine dose adjustments are required for older adults or in cases of renal or hepatic impairment.

Research Evidence / Overview of Studies for Пимафуцин (Natamycin)

This overview summarizes the research that has been conducted on Natamycin, the active ingredient in Пимафуцин, to help users understand what the scientific findings have observed so far and where limitations or gaps in the evidence exist. This information is purely descriptive.

---

Evidence for Vulvovaginal Candidiasis (VVC)

Research examining Natamycin for vulvovaginal candidiasis has been conducted using Randomized Controlled Trials (RCTs) and systematic reviews. Researchers typically monitored two main types of outcomes: clinical outcomes (based on changes in patient-reported symptoms like itching and discharge) and microscopic recovery (based on laboratory confirmation of fungal presence).

However, long-term effects are not fully established. The research provides limited insight into Natamycin’s potential role in the prevention of relapse for individuals who experience frequently recurring VVC, as follow-up durations were often limited.

---

Evidence for Fungal Keratitis (Infection of the Cornea)

Natamycin was studied for use in fungal keratitis, a fungal infection of the eye, in large-scale RCTs and meta-analyses. Studies examined outcomes such as changes in visual acuity (sharpness of vision) and the incidence of adverse events, including the frequency of therapeutic corneal transplant.

Research describes limitations related to the depth of the drug’s ability to penetrate the cornea, which is a factor researchers monitor in the study design. Data are limited regarding the long-term outcomes for the continued preservation of patient vision.

---

Evidence for Intestinal Candidiasis and Research Gaps

Research for intestinal fungal colonization involved controlled trials and small-scale studies. The main focus was on outcomes related to achieving a negative fungal culture from the digestive system and monitoring the pattern of recurrence. Data show patterns related to re-colonization occurring after treatment was stopped, and certainty remains low for this application, as sample sizes were modest.

Across all studied conditions, a primary limitation documented in the research is short follow-up durations, which limits understanding of long-term outcomes and relapse prevention. Furthermore, evidence is limited regarding the use of Natamycin in certain groups, such as children or patients with complex underlying health conditions, meaning that study results apply only to the populations studied.

Key Studies & References

1. Natamycin vs. Voriconazole for Fungal Keratitis – The Mycotic Ulcer Treatment Trial (MUTT)

Common questions about Пимафуцин (FAQ)

---

Q: How does Pimafucin differ from other remedies for thrush (candidiasis)?

A: Official regulatory documents describe Natamycin, the active substance in Pimafucin, as belonging to the polyene macrolide antibiotic class. Its mechanism of action is highly specific, involving binding to ergosterol—a substance found only in fungal cell membranes. This specific mechanism is documented as being distinct from other groups of antifungal medicines.

Q: After how many days can the effect of Pimafucin be expected?

A: Official patient information for certain formulations of Natamycin indicates that if there is no clinical improvement in symptoms within a period of approximately 7 to 10 days, medical advice should be sought. This timeframe is typically when patients are advised to assess their symptoms in consultation with a healthcare professional.

Q: What should be done if I miss a dose of Pimafucin?

A: Official patient information generally describes the procedure of taking the missed dose as soon as it is remembered. However, if it is almost time for the next scheduled dose, the forgotten dose should be skipped to return to the usual schedule. Regulatory guidance states that taking a double dose to compensate for a missed dose is not recommended.

Q: Can Pimafucin be used if other antifungal treatments have not been successful?

A: Regulatory reviews of Natamycin note that the development of acquired resistance to the active substance in fungi is rarely observed in laboratory settings, and reports of clinical resistance are limited. This characteristic is a documented factor in the regulatory review of the drug's properties.

Q: What should be done if unusual or severe side effects occur?

A: Official instructions typically state that medical assistance should be sought immediately if signs of an allergic reaction or any other serious or worsening side effects develop. This guidance is a standard regulatory requirement for all pharmaceutical products.

Q: Can Pimafucin and other local treatments be used at the same time?

A: Official prescribing information for the ophthalmic (eye drop) form of Natamycin specifies that if other local eye medications are being used, a time interval of at least 5 to 10 minutes must be observed between applications. This is a procedural constraint designed to prevent the active substance from being washed out.

Q: Do any foods or drinks affect the action of Pimafucin?

A: Regarding the oral tablets of Pimafucin, official instructions indicate that they can be taken independently of food intake (with or without food). For the topical and vaginal formulations (cream, suppositories), an impact from food or drinks is not expected due to the minimal systemic absorption of the active ingredient.

Q: What research has been conducted on the safety of long-term use of Pimafucin?

A: While preclinical studies show the active substance has low acute toxicity, the sections related to human research often note a key limitation. Studies frequently have short observation periods, meaning data on long-term safety and the potential for preventing chronic recurrence are limited.

Q: What information about Pimafucin is available in foreign official documents (FDA, EMA)?

A: Information materials regarding Natamycin are available in the official databases of various regulators, including the FDA (United States), EMA (Europe), and TGA (Australia). These documents reflect its status as an antifungal agent with minimal systemic absorption, describing its available dosage forms and approved indications.

Q: Does Pimafucin have a sedative effect or affect driving ability?

A: Due to the lack of systemic absorption of Natamycin, official documents generally indicate that Pimafucin has no effect on the ability to drive or operate machinery. An exception is noted for the ophthalmic suspension, which may cause temporary visual disturbance and require caution.

Q: When should the use of Pimafucin be stopped if there is no effect?

A: Official documents, particularly for infections like keratitis, state that if no clinical improvement is observed within 7 to 10 days of use, a reassessment of the treatment plan should be considered. Any decision to stop or change the treatment regimen requires consultation with a healthcare provider.

Q: Can I stop using Pimafucin earlier if I feel better?

A: Official patient information often describes the importance of completing the full course of treatment, even if symptoms have cleared. This is done to help prevent the fungal infection from recurring or relapsing, consistent with standard regulatory guidance for antifungal therapy.

Q: Has fungal resistance to Pimafucin been reported?

A: Regulatory pharmacodynamic reviews of the active substance Natamycin note that resistance of fungal strains to the drug tends to develop slowly. Furthermore, primary resistance is reported to be rare, which is a documented aspect of its official profile.

Q: What is the probability of recurrence after treatment with Pimafucin?

A: Official summaries of scientific evidence acknowledge that studies on Natamycin often have limited follow-up duration. Due to this limitation, the role of the drug in preventing long-term recurrence is not fully established, and individual prediction regarding recurrence is not addressed in these studies.

Q: Does Pimafucin affect the microflora of the intestine or vagina?

A: Natamycin is specifically an antifungal agent that shows fungicidal activity against yeasts and molds. Scientific reports used by regulators indicate that Natamycin is not active against bacteria and is therefore not expected to interfere with the normal bacterial microflora.

Q: How long can Pimafucin be stored after the packaging is opened?

A: Official instructions for certain formulations, such as the cream, establish a specific shelf life after the initial opening of the tube, which is often stated as no more than one month. Unopened packages must be stored according to the temperature requirements and expiration date listed on the box.

Q: What is the difference between the cream, suppositories, and tablets of Pimafucin?

A: The key difference lies in the site of application (route of administration) and the approved indications. The cream is intended for topical application, the suppositories are for vaginal use, and the tablets are for oral intake, specifically targeting action within the intestinal tract.

Q: Can Pimafucin be used to prevent fungal infections?

A: The official indications for use of Natamycin (Pimafucin) define its purpose as being for the treatment (therapy) of fungal infections caused by susceptible pathogens, rather than for their prevention (prophylaxis).

Q: What symptoms might indicate intolerance to the inactive ingredients in Pimafucin?

A: Intolerance to inactive components, similar to hypersensitivity to the active component, is listed as a contraindication in official documents. Symptoms of intolerance typically involve local reactions such as irritation, burning, or redness at the site of application, or in rare cases, systemic allergic reactions.

Storage and Protection Requirements

Official regulatory documents define specific storage conditions for Пимафуцин (Natamycin) to ensure product stability and efficacy. The medicine must generally be stored at a temperature not exceeding 25 C or within the range of 2 C to 24 C for the ophthalmic suspension. It is mandatory to keep the product in its original container, tightly closed, and protected from light and excessive heat.

Handling and Disposal Mandates

Do not freeze the medicine in any form. All formulations must be stored out of the sight and reach of children. Regarding disposal, unused or expired medicine must not be thrown away with household waste or flushed down the toilet. Patients are instructed to consult a pharmacist for guidance on using an official medication take-back program to ensure proper pharmaceutical waste disposal.